NCT05896046View on ClinicalTrials.gov

SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 14, 2023

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2026

Conditions
Relapsed or Refractory Hodgkin Lymphoma
Interventions
DRUG

SHR2554+ SHR1701

SHR2554: 350mg/day, PO, twice a day. SHR1701: recommended dose from phase I trial, IV, over 30 minutes.

DRUG

SHR-1701

Phase I: 30-150 mg/kg, IV over 30 minutes. Phase II: recommended dose from phase I trial, IV over 30 minutes.

Trial Locations (1)

100853

RECRUITING

Han wei dong, Beijing

All Listed Sponsors
lead

Chinese PLA General Hospital

OTHER